"Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Patients with LAL deficiency (also known as Wolman disea"...
Oral poliovirus vaccine (OPV) contains live attenuated poliovirus (Sabin strain types 1, 2 and 3) and is intended for polio prophylaxis in infants 6-12 weeks of age, all unimmunized children up to 18 years of age, and high-risk adults. Adults, however, should receive the inactivated poliovirus vaccine (IPV). The attenuated virus particles in OPV are harvested from monkey kidney cell cultures and undergo an extensive purification process. OPV is administered multiple times to ensure immunity to all three types of poliovirus. Clinical studies reveal that OPV is highly effective in preventing natural poliovirus-induced neurologic sequelae. OPV received FDA approval in1963.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Orimune Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.